Blackhawk Growth Corp (BLR) Quote

This thing is doing great on the Canada exchange.

Beware. Company is nothing less than a shady operation. Placed on suspended grey market, reverse split shafting shareholders, wash rinse repeat here. Stay away!

This poc is so bad that even after a reverse split of 25 for 1, the bid didn't increase. I've never seen that despite being in 7-10 other reverse split crap holes.

Warning... Nothing here but a share sale program. Now you know.

Congrats corporate for a consistent program of screwing your shareholders. Now a reverse split from a big pile of crap to a smaller condensed crap pile. Any and all potential shareholders need to stay away from this dung pile. You've been given notice.

What a big nothing here. Garbage in and out..

Mr. Pels is working hard here. I like it!

Blackhawk Granted Rights to Distribute Emergency Use Authorized PCR Test Kit and Additional Emergency Use Authorized Covid-19 Antibody Test
8:31 AM ET 9/3/20 | Dow Jones
Blackhawk Granted Rights to Distribute Emergency Use Authorized PCR Test Kit and Additional Emergency Use Authorized Covid-19 Antibody Test

September 03, 2020 -- (Blackhawk Growth Corp.) --

(TheNewswire)Vancouver, British Columbia - TheNewswire - September 3, 2020 - Blackhawk Growth Corp. (CSE:BLR) (CNSX:BLR.CN) (OTC:BLRZF) (the "Corporation" or "Blackhawk"), is pleased to announce that it has entered into a definitive distribution agreement (the "Distribution Agreement"), dated effective August 31, 2020, with Medigen Biotechnology Corporation ("MBC")its affiliate company, TBG Biotechnology Corp. ("TBG") and a local agent, Boshic Advanced Materials Co., Ltd. ("Boshic") to distribute certain diagnostic products, including an ExProbe SARS-CoV-2 Testing Kit and a SARS-CoV-2 IgG/IgM Rapid Test Kit (collectively, the "Test Kits") used in the detection of antibodies associated with COVID-19. The Distribution Agreement replaces the memorandum of understanding entered into between Blackhawk, MBC and TBG, dated effective August 3, 2020.

About the ExProbe SARS-CoV-2 Testing Kit Click Image To View Full Size

About the SARS-CoV-2 IgG/IgM Rapid Test Kit Click Image To View Full Size

*taken from TBG's corporate presentation

The Distribution Agreement grants Blackhawk the non-exclusive right to distribute the Test Kits in North and South America, including Canada and the United States. The ExProbe SARS-CoV-2 Testing Kit has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for use in the United States by authorized laboratories, as of June 10, 2020, and the SARS-CoV-2 IgG/IgM Rapid Test Kit has received Emergency Use Authorization from the FDA on August 31st, 2020.

While sale of both the ExProbe SARS-CoV-2 Testing Kit as well as the SARS-CoV-2 IgG/IgM Rapid Test Kit are permitted in the United States, neither of the Test Kits have been approved by Health Canada. Blackhawk intends to submit the Test Kits for Health Canada approval. Both MBC and TBG have committed to supporting Blackhawk's efforts to obtain and maintain all necessary certifications and approvals for the sale and marketing of the Test Kits in Canada by granting access to all necessary documentation and studies concerning the Test Kits. Once Health Canada approval is granted, Blackhawk would be the exclusive and sole distributor in Canada provided minimum order and sales levels are maintained.

There can be no guarantee that Health Canada approval will be received once an application is completed.

In consideration for the ongoing rights to distribute the Test Kits, Blackhawk will use its best efforts to achieve certifications and licenses for the distribution of the Test Kits in Canada and South America and has agreed not to distribute any other COVID-19 rapid antibody test products in North and South America. Blackhawk is also required to maintain certain minimum sales levels in order to retain rights under the Distribution Agreement, which include purchasing at least 50,000 Test Kits within the initial three months of the Distribution Agreement and purchasing at least 200,000 Test Kits within six months. Failure to achieve minimum sales levels could result in the termination of the Distribution Agreement, and the loss of all rights to distribute the Test Kits. No cash will be paid, or securities issued, in consideration for the grant of the distribution rights.

The Corporation is at arm's length from both MBC, TBG and Boshic. The grant of the distribution rights to the Test Kits neither constitutes a fundamental change or change of business for the Corporation, nor will it result in a change of control of the Corporation within the meaning of applicable securities laws and the policies of the Canadian Securities Exchange. No securities of the Corporation will be issued in connection with the transactions contemplated by the Distribution Agreement.

Readers are cautioned that the Corporation has not independently verified testing statistics and data provided by MBC and TBG. The Corporation has not received any assurances as to the timeline for the manufacturing and distribution of the Test Kits in North and South American, or as to the capacity of MBC and TBG to produce a sufficient volume of the Test Kits to make distribution economically feasible.

"I am excited to announce the closing of this deal" says Frederick Pels, CEO of Blackhawk. "We wanted to negotiate more than just a deal, but a true partnership and I am certain we achieved that here. I look forward to working with TBG, Medigen and Boshic to provide an extremely needed and superior quality product. We combed through every detail to ensure a harmonious and effective deal that separates us from the pack and I anticipate the relationship to grow substantially over the coming months and look forward to updating our shareholders with our upcoming initiatives."

"We are pleased indeed to collaborate with such a motivated and committed company as Blackhawk" says Stanley Chang, Chairman of Medigen and TBG. "We are engaged in the business of in vitro diagnostic test for the past 20 years, and facing COVID-19 pandemic, we provided comprehensive testing solutions and products of high quality. Joining our strength together with Blackhawk and Boshic, we expected to see the business of our Test Kits flourishing in North and South America and help more people fighting against COVID-19 pandemic."

About Medigen Biotechnology Corp.

Established in late 1999, Medigen Biotechnology Corp. (MBC) is a publicly traded company listed on the Taiwanese Stock Exchange. The company upholds the vision of "Innovations for a better life" focusing on the development of new therapies for liver diseases and cancers.

MBC has now developed into a comprehensive biopharmaceutical corporation with business fields covering new drug development, innovative drug discovery, molecular diagnostics, vaccine, and generic drugs. Combining Taiwan's biomedical research capabilities, international clinical development experiences and competitiveness in commercialization of state-of-the-art technologies, Medigen has built up a portfolio of patent protected projects which will be transformed into products approved by the regulatory bodies of various countries. For more information on Medigen, please visit their website here: http://www.medigen.com.tw/en/home/

About TBG Biotechnology Corp.

TBG Biotechnology Corp. (TBG) is a global molecular diagnostics company dedicated to the development, manufacture and marketing of molecular diagnostics kits, instruments and services. With its research and development based in the US, Taiwan and China, TBG manufactures its products in its ISO13485 certified facility in Xiamen, China serving the clinical labs of both hospitals and independent reference labs, blood centers and bone marrow registry labs around the world.

For more information on TBG, please visit their website here: http://www.tbgbio.com/en

For further information please contact:

Frederick Pels, Chief Executive Officer

(403)-991-7737

fred@blackhawkgrowth.com

Cautionary Note Regarding Forward-Looking Statement

All statements in this press release, other than statements of historical fact, are "forward-looking information" with respect to the Corporation within the meaning of applicable securities laws, including with respect to completion of the acquisition of the distribution rights for the Test Kits, the approval of the Test Kits by the United States Food and Drug Administration, and Health Canada, and the marketing and distribution of the Test Kits in North and South America. The Corporation provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited those identified and reported in the Corporation's public filings under the Corporation's SEDAR profile at www.sedar.com. Although the Corporation has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. The Corporation disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.

Copyright (c) 2020 TheNewswire - All rights reserved.

> Dow Jones Newswires

September 03, 2020 08:31 ET (12:31 GMT)

What a pos company...

Interesting development

https://www.thenewswire.com/press-releases/1k98FDQ3K-blackhawk-acquires-california-based-licensed-cannabis-producer.html

I think I detect a heartbeat.

Did you read the letter to shareholders?? Yeah...neither did I...

No alibis, Blackhawk?

S.E.C. should also investigate the sellers on this stock. A lot of shares dumped before suspension. How convenient...or did they know?
Would like to receive updates on investigation and actions taken against it. I'd also like to see the agency appoint an adjudicator and appropriations of compensations to shareholders. I think all of the above would go a long way towards other companies acting in similar manner.

Yep... Hope they're screwed and get payback..

Well if it's a loss, and probably is, hope management gets indicted and jail time for being shady scumbags..

BLRZF SEC Suspension "due to questions and concerns regarding the accuracy and adequacy of publicly available information concerning Blackhawk and the market for its securities, including public statements made by Blackhawk in press releases dated April 22 and 29, 2020, and May 10 and 11, 2020, and in video interviews dated April 16 and 22, 2020, and May 1, 2020, regarding Blackhawk’s purported agreement to distribute COVID-19 antibody test kits in the United States and other countries, and its sales and delivery of those test kits."

https://www.sec.gov/litigation/suspensions/2020/34-89122.pdf

Order:

https://www.sec.gov/litigation/suspensions/2020/34-89122-o.pdf

I'm not convinced that this isn't another scam.

either was the sec.

Yeah unless there is some legs to the fluff press releases, it looks like dilution pollution. I got a few shares after their test kits press release but I haven't and wouldn't add. I'm not convinced that this isn't another scam. So...pay more if it's legit. At least you won't lose your monies.

I'm not sure where this is going, but its beginning to look like more zeros in front of the one.

Been here a while, not a lot of shares on my end, but I wouldn't suggest buying into this company. Stocks dead and I'm only seeing dilution. Lots of other plays that are better.

So, is this cannabis company making money or are we looking at warrants or a reverse split?

Come on corporate...one Big dud here...

And we are on the bottom floor of the elevator. Going up?

its coming,much more,many things in works!!

Hoping for MDEL approval in Canada.

Stick a fork in it...she's dead...
Glad I don't have a lot of shares here.
Made and making money on everything else but this turd...

patience will pay,not easy when watching other tickers go up,but at least not losing $$$

Well..another week of sit and stare. Difficult to add for a variety of reasons. Maybe next week.

So much potential here, and its setting up nicely. Best place that I know of to be right now.

Spreads and mm jostling. This is going nowhere fast. Anybody got some technicals to share?

news today> https://www.otcmarkets.com/stock/BLRZF/news/story?e&id=1607343

Yeah it's not even really tradeable. Also any buying gets selling pressures. Probably note conversion??

big gap=insane low float,and not any sellers,lowering their ask until its a tick away from bid,

Sir Patrick Vallance, the government’s chief scientific adviser, and Prof Chris Whitty, Boris Johnson’s chief medical adviser, sought to reassure the public. Those who have had the virus once will develop some immunity, they said – and it is rare to get an infectious disease again.everyone needs this test,if you had cv19,your good to go anywhere,dont need a vaccine,and they want to know how many ppl had symptoms,how severe,ect.
everyone will want to take this test before being injected with some government cocktail that may or maynot work,or may cause more harm!!

Looks like these kits are used to determine if you have had the virus. Its a quick test, but not the correct one to determine whether you now have the virus (or not). It won't get you in the ballgame.

not bad volume,for a fri,monday interesting,word spreading,contract news and updates are coming!!

As soon as these test kits become more available, their use will change from a stop gap monitor to a golden pass. It'll get you into any church, park, beach or pub. Just pass the test. My opinion, of course.

Big gap spread. Obviously intended to go nowhere quick. Ridiculous...

Is it practical to have the President, his team of covid-19 experts, and the news media tested prior to each news conference with this type of test? They could stay inside, sit closer, and need no mask.

ceo,making developments happen,news every few days(not outlandish bs,with empty promises),many divisons,many things to come,i am excited to be in the right place at the right time,as big contracts coming,and revenues begin from multiple streams

fresh news out,https://www.otcmarkets.com/stock/BLRZF/news/story?e&id=1603004

ss updated,outstanding 163,385,184/mkt cap 3,267,704

warrants are Canadian exchange only,not otc

manufacturer can make 200,000per day,6day delivery to customer,proven

Thanks for the research and links. Do you have a fair market value stock price? Notice they have .05 warrants. What obstacle do they pose if exercised?
Currently long with 15k shares..

Ah, the owners and the players provide funding for a virus testing station. Fans buy tickets as normal, but must be tested at a lab adjacent to the ballpark. After a short wait, those who pass the test are allowed to enter the stadium... with their masks in their pockets. Play ball!!

Could it become commonplace at the arena... Get a test, get a ticket.

This test kit seems to be a fast and effective one. In my opinion, testing will become very common and almost routine. The big question may become who has the kits and when can they be shipped. Sure, they are made in China, but demanders will not care.